OncoMatch/Clinical Trials/NCT07023315

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Is NCT07023315 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Cadonilimab and SOX chemotherapy for gastric and gastroesophageal junction (gej) adenocarcinoma.

Phase 3RecruitingAkesoNCT07023315Data as of May 2026

Treatment: Cadonilimab · SOX chemotherapy — This study investigates treatment of cadonilimab or placebo combined with SOX chemotherapy (oxaliplatin + tegafur-gimeracil-oteracil potassium) given before surgery (neoadjuvant) and cadonilimab or placebo combined with SOX chemotherapy after surgery (adjuvant), will work and be safe for the treatment of resectable (removable by surgery) gastric or gastroesophageal cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Gastric Cancer

Esophageal Carcinoma

Disease stage

Required: Stage T3-4AN+M0, T4BNANYM0 (AJCC 8th edition)

Excluded: Stage UNRESECTABLE LOCALLY ADVANCED DISEASE, DISTANT METASTASIS

clinical stage T3-4aN+M0 or T4bNanyM0 per AJCC 8th edition

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-cancer therapy

Has received prior anti-cancer therapy for the current malignancy

Lab requirements

Blood counts

Kidney function

Liver function

Has adequate organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify